Arcutis Presents New Patient-Reported Outcome Data For ZORYVE Cream 0.15% In Atopic Dermatitis At American College Of Allergy, Asthma And Immunology 2024 Annual Scientific Meeting
Arcutis Presents New Patient-Reported Outcome Data For ZORYVE Cream 0.15% In Atopic Dermatitis At American College Of Allergy, Asthma And Immunology 2024 Annual Scientific Meeting
- New patient-reported outcome data from INTEGUMENT-1 and -2 demonstrate that ZORYVE cream 0.15% rapidly decreased the impact of atopic dermatitis (AD), including sleep loss and daily activities, on patients and families
- ZORYVE cream 0.15% resulted in significant improvements across all efficacy endpoints, including validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Success and rapid itch reduction within 24-hours of first application
- Data presented as an oral presentation at the American College of Allergy, Asthma and Immunology (ACAAI) 2024 Annual Scientific Meeting
- INTEGUMENt-1和-2的新患者報告結果數據表明，ZORYVE 0.15%乳膏迅速減輕了特應性皮炎（AD）對患者和家庭的影響，包括睡眠喪失和日常活動。
- ZORYVE 0.15%乳膏在所有有效性終點上均取得顯著改善，包括經驗證的調查全球評估-特應性皮炎（vIGA-AD）成功和在首次使用後24小時內迅速減輕瘙癢。
- 數據在美國過敏、哮喘和免疫學學院（ACAAI）2024年年度科學會議上以口頭報告形式呈現。
WESTLAKE VILLAGE, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new patient-reported outcome data demonstrating that ZORYVE cream 0.15% improved the impact of AD on patients, families, and caregivers. These results, along with efficacy, safety, and tolerability data from Phase 3 INTEGUMENT-1 and -2, will be shared in an oral presentation at the ACAAI 2024 Annual Scientific Meeting held October 24-28, 2024, in Boston, MA.
WESTLAKE VILLAGE，加利福尼亞州，2024年10月24日（GLOBE NEWSWIRE）- Arcutis Biotherapeutics, Inc.（納斯達克：ARQT）是一家專注於在免疫皮膚病學領域開發有意義創新的商業化生物製藥公司，今天宣佈了新的患者報告結果數據，表明ZORYVE 0.15%乳膏改善了AD對患者、家庭和護理人員的影響。這些結果，以及來自INTEGUMENt-1和-2第3階段的有效性、安全性和耐受性數據，將在即將於2024年10月24日至28日在馬薩諸塞州波士頓舉行的ACAAI 2024年年度科學會議上以口頭報告形式分享。
Improvement with ZORYVE cream 0.15% was seen across multiple patient-reported outcomes including SCORing AD (SCORAD) total scorei, Patient-Oriented Eczema Measure (POEM), and Dermatitis Family Impact (DFI) compared to vehicle at 4 weeks, with improvement reported as early as Week 1, the first timepoint measured. These assessments score the improvement of physical symptoms such as redness and itchiness, as well as impact on loss of sleep, emotional distress, and daily activities (such as schoolwork, housework, or social activities).
ZORYVE 0.15%乳膏的改善在多項患者報告結果上均有所表現，包括SCORing AD（SCORAD）總得分，以及與4周的載具相比的患者定向溼疹評估（POEM）和皮炎家庭影響（DFI）得分，在第1周即可看到改善，這是第一次測量的時間點。這些評估評分包括身體症狀的改善，如紅腫和瘙癢，以及對睡眠喪失、情感困擾和日常活動（如學業、家務或社交活動）的影響。
譯文內容由第三人軟體翻譯。
